http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 22 Jun 2026 08:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Press+Releases/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html <p>AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Hc1pZoAUg5w_dZteoWTFqX7Aff7l6_qSZRLrMNnKuQE60dXQf8F3v50kh1RKP8asURLXzMw-QZfrHfxHYvW7OvJ-JGt9GuPypcs1kK1KYtDxV4ri6Dnmb5nEeQ72pOKJxSIdSch6guxZZFuVJ4eUGmseaYZZ6JBsnCljJ9ofGbyBrw7WgwzJkrtVDDKksGXDK3Z0laJcXkmPXRDVp9HLqod_k1ln0DKfvW4yjNCJQ6RP6qm5GN7A4MR54tfZW7HFxpJry_NYk8_TPGDARj3R8W0hyS7kY6YiGX1LSoabcTvhrQSDelfeOqwbhIs3g0LM" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people worldwide are <a href="https://www.globenewswire.com/Tracker?data=aCkkLZZuI3QeTJ3D8gncxeDO-b60eZStJ-TVvmB_unO2lfpLEMW57Ksn7JdcPMg9WoHGNtz_yVJx82BP5zh6RQ==" rel="nofollow" target="_blank">living</a> with MS today, and despite decades of research, every approved treatment falls short of the same fundamental goal: stopping the disease cold. Current therapies can slow progression, but they cannot halt it, and for millions of patients, that gap means a future of worsening disability. Now, <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (CSE: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=5mjvShYWUslDUK-qWq3yOY4A0SasiMo0EIYaoscXm2jYC_vbd7h1qoZuNiiqRhc5aXLjKXRCROhMC7fP7WHIAg==" rel="nofollow" target="_blank">profile</a>) http://www.streetinsider.com/Globe+Newswire/Novel+Patented+Myelin+Drug-Discovery+Strategy+Targets+Massive+Unmet+Need+in+Multiple+Sclerosis/26670385.html Mon, 22 Jun 2026 08:30:00 -0400 BIIB BIIB CLNN CLNN QNTM SNY SNY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Clene+Inc.++++++++++++++++For%3A+Jun+11++Filed+by%3A+Mortenson+Mark/26646714.html si-local-file:///var/storage/secattach/20260615/26646714.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Clene+Inc.++++++++++++++++For%3A+Jun+11++Filed+by%3A+Mortenson+Mark/26646714.html Mon, 15 Jun 2026 14:24:00 -0400 CLNN O.50600729 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Clene+Inc.++++++++++++++++For%3A+Jun+11++Filed+by%3A+Mortenson+Mark/26646714.html si-local-file:///var/storage/secattach/20260615/26646714.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Clene+Inc.++++++++++++++++For%3A+Jun+11++Filed+by%3A+Mortenson+Mark/26646714.html Mon, 15 Jun 2026 14:24:00 -0400 CLNN O.50600729 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Clene+Inc.++++++++++++++++For%3A+Jun+11++Filed+by%3A+BROWN+MORGAN+R/26646706.html si-local-file:///var/storage/secattach/20260615/26646706.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Clene+Inc.++++++++++++++++For%3A+Jun+11++Filed+by%3A+BROWN+MORGAN+R/26646706.html Mon, 15 Jun 2026 14:23:00 -0400 CLNN O.50600729 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Clene+Inc.++++++++++++++++For%3A+Jun+11++Filed+by%3A+BROWN+MORGAN+R/26646706.html si-local-file:///var/storage/secattach/20260615/26646706.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Clene+Inc.++++++++++++++++For%3A+Jun+11++Filed+by%3A+BROWN+MORGAN+R/26646706.html Mon, 15 Jun 2026 14:23:00 -0400 CLNN O.50600729 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Clene+Inc.++++++++++++++++For%3A+Jun+11++Filed+by%3A+Etherington+Robert+Dee/26646708.html si-local-file:///var/storage/secattach/20260615/26646708.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Clene+Inc.++++++++++++++++For%3A+Jun+11++Filed+by%3A+Etherington+Robert+Dee/26646708.html Mon, 15 Jun 2026 14:23:00 -0400 CLNN O.50600729 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Clene+Inc.++++++++++++++++For%3A+Jun+11++Filed+by%3A+Etherington+Robert+Dee/26646708.html si-local-file:///var/storage/secattach/20260615/26646708.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Clene+Inc.++++++++++++++++For%3A+Jun+11++Filed+by%3A+Etherington+Robert+Dee/26646708.html Mon, 15 Jun 2026 14:23:00 -0400 CLNN O.50600729 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Clene+Inc.+++++++++++++++++++++++++++/26611113.html si-local-file:///var/storage/secattach/20260605/26611113.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Clene+Inc.+++++++++++++++++++++++++++/26611113.html Fri, 05 Jun 2026 16:10:00 -0400 CLNN O.50600729 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Clene+Inc.+++++++++++++++++++++++++++/26611113.html si-local-file:///var/storage/secattach/20260605/26611113.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Clene+Inc.+++++++++++++++++++++++++++/26611113.html Fri, 05 Jun 2026 16:10:00 -0400 CLNN O.50600729 http://www.streetinsider.com/SEC+Filings/Form++SD+++++++++Clene+Inc.+++++++++++++++++++++++++++/26542520.html si-local-file:///var/storage/secattach/20260522/26542520.html http://www.streetinsider.com/SEC+Filings/Form++SD+++++++++Clene+Inc.+++++++++++++++++++++++++++/26542520.html Fri, 22 May 2026 16:44:00 -0400 CLNN O.50600729 http://www.streetinsider.com/SEC+Filings/Form++SD+++++++++Clene+Inc.+++++++++++++++++++++++++++/26542520.html si-local-file:///var/storage/secattach/20260522/26542520.html http://www.streetinsider.com/SEC+Filings/Form++SD+++++++++Clene+Inc.+++++++++++++++++++++++++++/26542520.html Fri, 22 May 2026 16:44:00 -0400 CLNN O.50600729 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clene+Inc.++++++++++++++++For%3A+May+18/26542450.html si-local-file:///var/storage/secattach/20260522/26542450.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Clene+Inc.++++++++++++++++For%3A+May+18/26542450.html Fri, 22 May 2026 16:37:00 -0400 CLNN O.50600729